Lineage Cell Therapeutics (LCTX) Current Assets (2010 - 2026)

Lineage Cell Therapeutics' Current Assets history runs 17 years deep, the most recent figure standing at $56.2 million for Q1 2026.

• In Q1 2026, Current Assets rose 12.36% year-over-year to $56.2 million; the TTM figure through Mar 2026 stood at $56.2 million (up 12.36% YoY), while the FY2025 annual figure was $59.2 million, up 16.0% from the prior year.
• Current Assets for Q1 2026 stood at $56.2 million, down from $59.2 million in the prior quarter.
• The five-year high for Current Assets was $81.9 million in Q1 2022, with the low at $34.4 million in Q3 2024.
• The 5-year median for Current Assets is $49.7 million (2023), against an average of $52.2 million.
• The sharpest annual moves came in 2022 and 2024: Current Assets tumbled 46.21% in 2022, then surged 32.66% in 2024.
• Lineage Cell Therapeutics' Current Assets stood at $60.0 million in 2022, then tumbled by 35.93% to $38.4 million in 2023, then soared by 32.66% to $51.0 million in 2024, then increased by 16.0% to $59.2 million in 2025, then decreased by 5.06% to $56.2 million in 2026.
• Business Quant data shows LCTX's Current Assets at $56.2 million in Q1 2026, $59.2 million in Q4 2025, and $42.3 million in Q3 2025.